Technical Analysis for ARDX - Ardelyx, Inc.

Grade Last Price % Change Price Change
grade F 2.99 -2.92% -0.09
ARDX closed down 2.92 percent on Friday, May 17, 2019, on 60 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ARDX trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
200 DMA Resistance Bearish -2.92%
Spinning Top Other -2.92%
Bollinger Band Squeeze Range Contraction -2.92%
Lower Bollinger Band Walk Weakness -2.92%
BB Squeeze + Lower Band Touch Range Contraction -2.92%

Older signals for ARDX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Biotechnology Biopharmaceutical Chronic Kidney Disease End Stage Renal Disease Metabolic Diseases Astrazeneca Rockwell Medical Södertälje Municipality Hyperphosphatemia
Is ARDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.85
52 Week Low 1.6
Average Volume 190,409
200-Day Moving Average 3.1502
50-Day Moving Average 3.2799
20-Day Moving Average 3.288
10-Day Moving Average 3.191
Average True Range 0.1888
ADX 23.23
+DI 13.4696
-DI 23.551
Chandelier Exit (Long, 3 ATRs ) 3.0836
Chandelier Exit (Short, 3 ATRs ) 3.5164
Upper Bollinger Band 3.5908
Lower Bollinger Band 2.9852
Percent B (%b) 0.01
BandWidth 18.418491
MACD Line -0.0604
MACD Signal Line -0.0131
MACD Histogram -0.0472
Fundamentals Value
Market Cap 141.86 Million
Num Shares 47.4 Million
EPS -2.44
Price-to-Earnings (P/E) Ratio -1.23
Price-to-Sales 0.00
Price-to-Book 1.59
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.16
Resistance 3 (R3) 3.17 3.12 3.13
Resistance 2 (R2) 3.12 3.08 3.12 3.12
Resistance 1 (R1) 3.06 3.05 3.03 3.05 3.11
Pivot Point 3.01 3.01 2.99 3.00 3.01
Support 1 (S1) 2.94 2.96 2.92 2.93 2.87
Support 2 (S2) 2.89 2.93 2.89 2.86
Support 3 (S3) 2.83 2.89 2.85
Support 4 (S4) 2.82